相关实验视频

Updated: Mar 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

微生物组和EGFR突变非小细胞肺癌:一个复杂的相互作用

Serena Eccher¹, Marco Sposito¹, Ilaria Mariangela Scaglione¹

¹Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Expert review of clinical immunology

|March 13, 2026

概括

肠道微生物群影响表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 治疗. 向微生物组可以提高EGFR氨酸激酶抑制剂 (TKI) 的有效性,并降低NSCLC患者的毒性.

科学领域:

在瘤学瘤学.
微生物组研究微生物组研究
药理学药理学是指药理学的学科.

背景情况:

表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 提出了独特的挑战,包括对EGFR氨酸激酶抑制剂 (TKI) 的耐药性和治疗毒性.
主体微生物组越来越多地被认为对EGFR向疗法的疗效和耐受性的潜在影响.

研究的目的:

审查EGFR突变NSCLC中微生物组的特征.
讨论肠道,呼吸道和内微生物组与EGFR-TKI治疗之间的相互作用.
探索增强TKI疗效和免疫治疗敏感性的策略.

主要方法:

文献综述总结了EGFR突变NSCLC中的微生物组特征.
分析与各种技术知识相关的微生物群差异变化.
对微生物向干预措施的临床前和早期临床数据的探索.

主要成果:

微生物组在调节NSCLC对EGFR-TKI的反应方面发挥着重要作用.
特定的微生物组组成与不同的TKI治疗有关.
针对微生物群的干预措施显示了提高TKI有效性和降低毒性的潜力.

结论:

在EGFR突变NSCLC中的微生物组研究为改进治疗结果提供了巨大的潜力.
针对微生物群的干预措施可以提高TKI的疗效,减轻毒性,并可能改善免疫疗法反应.
结合微生物组,代谢组和免疫分析的综合性研究对于个性化的临床策略至关重要.

关键词:

欧洲农业基金会 (EGFR) 是一个.非小细胞肺癌是非小细胞肺癌.微生物组是一个微生物组.瘤微环境是一个微环境.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...